Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001274173-25-000045
Filing Date
2025-02-14
Accepted
2025-02-14 11:34:51
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 7622
  Complete submission text file 0001274173-25-000045.txt   9757
Mailing Address 201 BISHOPSGATE LONDON X0 EC2M 3AE
Business Address 201 BISHOPSGATE LONDON X0 EC2M 3AE 442078181818
JANUS HENDERSON GROUP PLC (Filed by) CIK: 0001274173 (see all company filings)

EIN.: 000000000 | State of Incorp.: Y9 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 6282 Investment Advice
(CF Office: 02 Finance)

Mailing Address 5858 HORTON STREET #455 EMERYVILLE CA 94608
Business Address 5858 HORTON STREET #455 EMERYVILLE CA 94608 5105052680
4D Molecular Therapeutics, Inc. (Subject) CIK: 0001650648 (see all company filings)

EIN.: 473506994 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91921 | Film No.: 25625168
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)